Pipemidic acid suppliers

Pipemidic acid

CAS:: 51940-44-4

MF:: C14H17N5O3

MW:: 303.32

SecurityInformation

Symbol(GHS) ：: GHS08

Signal word ：: Danger

Hazard statements ：: H317-H334

Precautionary statements ：: P280-P302+P352

Hazard Codes ：: Xi

Risk Statements ：: 42/43

Safety Statements ：: 22-36/37-45

WGK Germany ：: 2

RTECS ：: UV1153800

HS Code ：: 29335990

Toxicity：: LD50 in mice (mg/kg): 4000 orally; 1000 i.p., 50 i.v. (Ficicchia)

Use：: An orally administered pyridopyrimidine derivative with a 7-piperazinyl moiety. The piperazinyl moiety at C-7 increases in-vitro activity against Ps. aeruginosa. Pipemidic acid is inactive against Gram-positive bacteria or anaerobes It is well absorbed orally. The drug is rapidly metabolized, primarily to acetyl, formyl and oxo derivatives, which exhibit much reduced antibacterial activity. It is eliminated in the urine, 50–85% of a dose appearing over the first 24 h, less than 2% as inactive metabolites. Non-renal clearance accounts for 10–40% of a dose in the young, rising to 40–70% in elderly subjects, thereby compensating for possible renal insufficiency. No dosage adjustment is necessary in patients with mild renal insufficiency. Some of the drug is eliminated in the bile and a significant portion appears in the feces. Nausea and vomiting are common; dizziness, weakness and grand mal seizures have been observed, principally in the elderly. A number of reactions have been sufficiently severe to require discontinuation of therapy. Clinical use is restricted to urinary tract infections.

More▼

You can find Pipemidic acid suppliers, manufacturers, and distributors from countries such as CHINA, United States and the Europe here. Browse to the tetrahydrofuran product information displayed by the supplier, as well as the supplier's contact and capability information.

Dideu Industries Group Limited